Articles liés

Zilurgisertib (Atebrioz)

Approved F.O.P. therapy marketed as Atebrioz; inhibits the ALK2 protein involved in directing bone growth.

• De nouveaux traitements offrent de l'espoir aux patients atteints du trouble osseux incontrôlable F.O.P.